Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17615246 | 0.95 | BACE1 (0.31) | AOC3BACE1 | |
| SCHEMBL19656340 | 0.85 | TERT (0.32) | BACE1 | |
| SCHEMBL19663592 | 0.78 | — | — | |
| SCHEMBL17691506 | 0.75 | — | — | |
| SCHEMBL1764760 | 0.74 | APP (0.30) | — | |
| SCHEMBL19656342 | 0.74 | RECQL (0.39) | — | |
| SCHEMBL22198892 | 0.72 | BACE1 (0.35) | BACE1 | |
| SCHEMBL28504369 | 0.72 | ROCK1 (0.38) | BACE1 | |
| SCHEMBL23090479 | 0.71 | SLC7A5 (0.40) | BACE1 | |
| SCHEMBL7142708 | 0.71 | PPIB (0.37) | BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230233697-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2023-07-27 | — | — | US | disclosed |
| US-11116845-B2 | Cytotoxic benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2021-09-14 | — | — | US | disclosed |
| EP-3778601-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | ImmunoGen, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| US-20200405870-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2020-12-31 | — | — | US | disclosed |
| US-10722588-B2 | Cytotoxic benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2020-07-28 | — | — | US | disclosed |
| EP-3189056-B1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN INC (US) | 2020-06-10 | — | — | EP | disclosed |
| US-20190269786-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2019-09-05 | — | — | US | disclosed |
| US-10238751-B2 | Cytotoxic benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2019-03-26 | — | — | US | disclosed |
| US-20170340748-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10238751-B2 | Cytotoxic benzodiazepine derivatives | GABRA6, GABBR1, GABRA5 | AOC3 3690/4885BACE1 2259/4885 |
| US-11116845-B2 | Cytotoxic benzodiazepine derivatives | GABRA6, GABBR1, GABRA5 | AOC3 3690/4885BACE1 2259/4885 |
| US-20200405870-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | GABRA6, GABBR1, GABRA5 | AOC3 3690/4885BACE1 2259/4885 |
| US-20230233697-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | GABRA6, GABBR1, GABRA5 | AOC3 3690/4885BACE1 2259/4885 |
| US-10722588-B2 | Cytotoxic benzodiazepine derivatives | GABRA6, GABBR1, GABRA5 | AOC3 3690/4885BACE1 2259/4885 |
| US-20190269786-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | GABRA6, GABBR1, GABRA5 | AOC3 3690/4885BACE1 2259/4885 |
| US-20170340748-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | GABRA6, GABBR1, GABRA5 | AOC3 3690/4885BACE1 2259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.